Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07303894) titled 'A Study of Isoquercetin in People With Ovarian Cancer' on Dec. 23, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Ovarian Cancer
Epithelial Ovarian Cancer
Serous Ovarian Tumor
Intervention:
Drug: Isoquercetin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 31, 2026
Target Sample Size: 90
Countries of Recruitment:
United States
To know more, visit https://clinicalt...